184 related articles for article (PubMed ID: 32822080)
1. Gastrointestinal pharmacology: practical tips for the esophagologist.
Scarpignato C; Sloan JA; Wang DH; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1481(1):90-107. PubMed ID: 32822080
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Proton Pump Inhibitors on Barrett's Esophagus.
Dunbar KB; Souza RF; Spechler SJ
Gastroenterol Clin North Am; 2015 Jun; 44(2):415-24. PubMed ID: 26021202
[TBL] [Abstract][Full Text] [Related]
3. Pharmacologic treatment of GERD: Where we are now, and where are we going?
Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
[TBL] [Abstract][Full Text] [Related]
4. The Role of Acid Suppression in Barrett's Esophagus.
Elias PS; Castell DO
Am J Med; 2017 May; 130(5):525-529. PubMed ID: 28159599
[TBL] [Abstract][Full Text] [Related]
5. Does Barrett's esophagus regress after surgery (or proton pump inhibitors)?
Spechler SJ
Dig Dis; 2014; 32(1-2):156-63. PubMed ID: 24603402
[TBL] [Abstract][Full Text] [Related]
6. The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Freedberg DE; Kim LS; Yang YX
Gastroenterology; 2017 Mar; 152(4):706-715. PubMed ID: 28257716
[TBL] [Abstract][Full Text] [Related]
7. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
8. Do proton pump inhibitors protect against cancer progression in GERD?
Miyashita T; Shah FA; Harmon JW; Marti GP; Matsui D; Okamoto K; Makino I; Hayashi H; Oyama K; Nakagawara H; Tajima H; Fujita H; Takamura H; Murakami M; Ninomiya I; Kitagawa H; Fushida S; Fujimura T; Ohta T
Surg Today; 2013 Aug; 43(8):831-7. PubMed ID: 23111465
[TBL] [Abstract][Full Text] [Related]
9. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
10. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
11. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
12. A review of pharmacotherapy for treating gastroesophageal reflux disease (GERD).
Savarino E; Zentilin P; Marabotto E; Bodini G; Della Coletta M; Frazzoni M; de Bortoli N; Martinucci I; Tolone S; Pellegatta G; Savarino V
Expert Opin Pharmacother; 2017 Sep; 18(13):1333-1343. PubMed ID: 28754071
[TBL] [Abstract][Full Text] [Related]
13. [Gastro-esophageal reflux through gastric antisecretory drugs].
Jian R
Gastroenterol Clin Biol; 2009; 33(8-9):614-24. PubMed ID: 19674856
[TBL] [Abstract][Full Text] [Related]
14. Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus.
Fabisiak A; Bartoszek A; Kardas G; Fabisiak N; Fichna J
Peptides; 2019 May; 115():27-31. PubMed ID: 30831146
[TBL] [Abstract][Full Text] [Related]
15. Poor effectiveness of proton pump inhibitors in non-erosive reflux disease: the truth in the end!
Scarpignato C
Neurogastroenterol Motil; 2012 Aug; 24(8):697-704. PubMed ID: 22783985
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic management of gastroesophageal reflux disease.
Ramakrishnan A; Katz PO
Curr Gastroenterol Rep; 2002 Jun; 4(3):218-24. PubMed ID: 12010622
[TBL] [Abstract][Full Text] [Related]
17. Bile reflux in benign and malignant Barrett's esophagus: effect of medical acid suppression and nissen fundoplication.
Stein HJ; Kauer WK; Feussner H; Siewert JR
J Gastrointest Surg; 1998; 2(4):333-41. PubMed ID: 9841990
[TBL] [Abstract][Full Text] [Related]
18. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
[TBL] [Abstract][Full Text] [Related]
19. Ask the doctor. Do PPI drugs for stomach acid reduce the risk of cancer in people (like me) with Barrett's esophagus?
Komaroff AL
Harv Health Lett; 2014 Apr; 39(6):2. PubMed ID: 24873004
[No Abstract] [Full Text] [Related]
20. Evolving pharmacological approaches in gastroesophageal reflux disease.
Altan E; Blondeau K; Pauwels A; Farré R; Tack J
Expert Opin Emerg Drugs; 2012 Sep; 17(3):347-59. PubMed ID: 22834684
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
